|
| Exchange Received Time 20/08/2019 16:53:57 Exchange Disseminated Time 20/08/2019 16:54:05 Time Taken 00:00:08 | Pursuant to regulation 30 of the SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we inform you that it has come to our knowledge that a complaint has been filed by Abraxis Biosciences LLC in the U.S. District Court for the District of New Jersey, which alleges that SPARC's filing of New Drug Application (NDA) for Taclantis® injection (Paclitaxel Injection Concentrate for Suspension) is an act of infringement of the Orange Book listed patents for Abraxane®.
SPARC believes that this lawsuit is without merit and will vigorously defend against these allegations. |
|
|